A CEO's view on the IPO window, finding the right partner

Sutro Biopharma Inc.'s "armed antibody" technology — aimed at creating the next generation of antibody-drug conjugates — recently nabbed a potential $298 million deal with Merck KGaA subsidiary EMD Serono...